查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1738458

Duchenne氏肌肉失养症治疗市场按治疗方法、治疗类型、最终用户和地区划分

Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, By End User, and By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 169 Pages | 商品交期: 2-3个工作天内

价格
简介目录

Duchenne氏肌肉失养症治疗市场规模预计在 2025 年为 89.887 亿美元，预计到 2032 年将达到 13881.81 亿美元，2025 年至 2032 年的复合年增长率为 47.85%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 89.887亿美元
效能数据 2020-2024 预测期 2025-2032
预测期：2025-2032年复合年增长率： 47.85% 2032年价值预测 138,818,100,000美元
图：2025年Duchenne氏肌肉失养症治疗市场占有率（%），依地区划分
杜氏肌肉营养不良症治疗市场-IMG1

Duchenne氏肌肉失养症(DMD) 是一种肌肉萎缩症。它是一种遗传性疾病，其特征是由于一种名为抗肌进行性Dystrophin的蛋白质（该蛋白质负责维持肌肉细胞完整）的变化而Duchenne氏肌肉失养症主要影响男性，但在极少数情况下，女性也可能患上这种疾病。

市场动态：

Duchenne氏肌肉失养症(DMD) 盛行率不断上升、对新型药物和治疗方法的需求不断增加、研发 (R&D)活性化以及公众对 DMD 和现有药物和治疗方法的认识不断提高是预计将促进全球Duchenne氏肌肉失养症治疗市场增长的主要因素。

例如，2022年5月，Stealth BioTherapeutics Corp.宣布，美国食品药物管理局（FDA）授予elamipretide孤儿药资格，用于治疗Duchenne氏肌肉失养症（DMD）。

此外，辉瑞公司计划于 2022 年 4 月在美国开设第一个试验点，进行 3 期试验，评估 fordaistrogene movaparvovec（一种临床实验微型Dystrophin萎缩蛋白基因疗法）对Duchenne氏肌肉失养症(DMD)门诊病人的效果。

本研究的主要特点

  • 本报告对Duchenne氏肌肉失养症治疗市场进行了详细分析，并提供了预测期 2025-2032 的市场规模和复合年增长率（以 2024 年为基准年）。
  • 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
  • 全球Duchenne氏肌肉失养症治疗市场的主要企业是根据公司亮点、产品系列、主要亮点、绩效和策略等参数进行分析的。
  • 人们相信，本报告的见解可以帮助负责人和公司经营团队就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
  • 全球Duchenne氏肌肉失养症治疗市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 透过用于分析全球Duchenne氏肌肉失养症治疗市场的各种策略矩阵，可以帮助相关人员做出决策。

目录：

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

  • 市场动态
    • Duchenne氏肌肉失养症盛行率不断上升
    • 缺乏标准化和严格的规章制度
    • 对新药和治疗方法的需求不断增加
  • 影响分析
  • 主要亮点
  • 监管情景
  • 产品发布/核准
  • PEST分析
  • 波特分析
  • 併购场景

4. 全球Duchenne氏肌肉失养症治疗市场-冠状病毒（COVID-19）大流行的影响

  • COVID-19流行病学
  • 供需侧分析
  • 经济影响

5. 2020 年至 2032 年全球Duchenne氏肌肉失养症治疗市场（依治疗方法及治疗类型）

  • 分子治疗方法
  • 类固醇治疗
  • 非类固醇消炎剂（NSAID）
  • 其他治疗方法和类型

6. 全球Duchenne氏肌肉失养症治疗市场（依最终用户划分），2020 年至 2032 年

  • 医院/诊所
  • 门诊中心
  • 其他最终用户

第七章Duchenne氏肌肉失养症治疗市场（按地区划分）2020 年至 2032 年

  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争态势

  • Pfizer Inc.
  • Fibrogen Inc.
  • BioMarin
  • Sarepta Therapeutics
  • Santhera Pharmaceuticals
  • PTC Therapeutics
  • NS Pharma Inc.
  • Nobelpharma Co. Ltd.
  • Bristol-Myers Squibb
  • Eli Lilly and Company

第九章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI898

duchenne muscular dystrophy treatment market size is estimated to be valued at US$ 8,988.7 Mn in 2025 and is expected to reach US$ 138,818.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 47.85% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 8,988.7 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 47.85% 2032 Value Projection: USD 138,818.1 Mn
Figure. Duchenne Muscular Dystrophy Treatment Market Share (%), By Region 2025
Duchenne Muscular Dystrophy Treatment Market - IMG1

Duchenne muscular dystrophy (DMD) is a form of muscular dystrophy. It is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of a protein called dystrophin, which helps keep muscle cells intact. DMD affects the muscles, leading to muscle wasting that gets worse over time. Duchenne muscular dystrophy occurs primarily in males, though in rare cases may affect females.

Market Dynamics:

Increase in prevalence of Duchenne muscular dystrophy (DMD), increase in demand for novel drugs or therapies, rise in research and development (R&D), and increase in awareness among people about DMD and available drugs/therapies are major factors expected to augment growth of the global Duchenne muscular dystrophy treatment market.

For instance, In May 2022, Stealth BioTherapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Elamipretide for the treatment of Duchenne Muscular Dystrophy (DMD).

Moreover, in April 2022, Pfizer Inc. planned to open the first U.S. sites in the Phase III study evaluating investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy (DMD).

Key features of the study:

  • This report provides in-depth analysis of the Duchenne muscular dystrophy treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global Duchenne muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., BioMarin, Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Fibrogen Inc., NS Pharma Inc., Nobelpharma Co. Ltd., Bristol-Myers Squibb, and Eli Lilly and Company.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global Duchenne muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Duchenne muscular dystrophy treatment market.

Detailed Segmentation:

  • Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type
    • Molecular-based Therapies
    • Steroid Therapy
    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • Other Therapeutic Approaches and Treatment Types
  • Global Duchenne Muscular Dystrophy Treatment Market, By End User
    • Hospitals/Clinics
    • Ambulatory Centers
    • Other End Users
  • Global Duchenne Muscular Dystrophy Treatment Market, By Geography
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles
    • Pfizer Inc.
    • Fibrogen Inc.
    • BioMarin
    • Sarepta Therapeutics
    • Santhera Pharmaceuticals
    • PTC Therapeutics
    • NS Pharma Inc.
    • Nobelpharma Co. Ltd.
    • Bristol-Myers Squibb
    • Eli Lilly and Company

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapeutic Approach and Treatment Type
    • Market Snapshot, By End User
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in prevalence of Duchenne muscular dystrophy
    • Lack of standardization and stringent rules/regulations
    • Increase in demand for novel drugs or therapies
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Duchenne Muscular Dystrophy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Molecular-based Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Steroid Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Other Therapeutic Approaches and Treatment Types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Duchenne Muscular Dystrophy Treatment Market, By End User, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals/Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Ambulatory Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Other End Users
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Duchenne Muscular Dystrophy Treatment Market, By Geography, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)

8. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fibrogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BioMarin
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sarepta Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Santhera Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • PTC Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NS Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Nobelpharma Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us